A tumor with a high level FGFR1 amp (C1037BL) and one with an FGFR1 R209H mutation (C1007BL), previously reported in Kallmann syndrome (Laitinen et al., 2011), had partial responses and prolonged benefit. Here, FGFR1 is linked to neoplasm.